JP2024510503A5 - - Google Patents
Info
- Publication number
- JP2024510503A5 JP2024510503A5 JP2023557352A JP2023557352A JP2024510503A5 JP 2024510503 A5 JP2024510503 A5 JP 2024510503A5 JP 2023557352 A JP2023557352 A JP 2023557352A JP 2023557352 A JP2023557352 A JP 2023557352A JP 2024510503 A5 JP2024510503 A5 JP 2024510503A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- sulfur
- nitrogen
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162477P | 2021-03-17 | 2021-03-17 | |
| US63/162,477 | 2021-03-17 | ||
| PCT/US2022/020479 WO2022197756A1 (en) | 2021-03-17 | 2022-03-16 | Plasma kallikrein inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510503A JP2024510503A (ja) | 2024-03-07 |
| JP2024510503A5 true JP2024510503A5 (enExample) | 2025-03-24 |
Family
ID=81327137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557352A Pending JP2024510503A (ja) | 2021-03-17 | 2022-03-16 | 血漿カリクレイン阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240382482A1 (enExample) |
| EP (1) | EP4308228A1 (enExample) |
| JP (1) | JP2024510503A (enExample) |
| CN (1) | CN117396474A (enExample) |
| WO (1) | WO2022197756A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3765459A1 (en) | 2018-03-13 | 2021-01-20 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
| EP4031245A1 (en) | 2019-09-18 | 2022-07-27 | Takeda Pharmaceutical Company Limited | Heteroaryl plasma kallikrein inhibitors |
| DK4031547T3 (da) | 2019-09-18 | 2024-09-09 | Takeda Pharmaceuticals Co | Plasmakallikreininhibitorer og anvendelser deraf |
| CN117396473A (zh) * | 2021-03-17 | 2024-01-12 | 武田药品工业株式会社 | 血浆激肽释放酶的咪唑并吡啶基抑制剂 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6887870B1 (en) * | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| ATE510827T1 (de) * | 2007-10-12 | 2011-06-15 | Ingenium Pharmaceuticals Gmbh | Inhibitoren von proteinkinasen |
| EP2627178B1 (en) * | 2010-10-11 | 2018-05-02 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as crth2 antagonists |
| EP3087067B1 (en) * | 2013-12-26 | 2018-10-24 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
| US10064869B2 (en) * | 2014-06-04 | 2018-09-04 | Thomas Helledays Stiftelse For Medicinsk Forskning | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions |
| WO2016010108A1 (ja) * | 2014-07-18 | 2016-01-21 | 塩野義製薬株式会社 | 含窒素複素環誘導体およびそれらを含有する医薬組成物 |
| US9815853B2 (en) | 2015-06-12 | 2017-11-14 | Global Blood Therapeutics, Inc. | Bridged bicyclic kallikrein inhibitors |
| DK3464271T3 (da) | 2016-05-31 | 2020-06-15 | Kalvista Pharmaceuticals Ltd | Pyrazolderivater som plasma-kallikreininhibitorer |
| EP3765459A1 (en) * | 2018-03-13 | 2021-01-20 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
-
2022
- 2022-03-16 CN CN202280033916.XA patent/CN117396474A/zh active Pending
- 2022-03-16 EP EP22714694.1A patent/EP4308228A1/en active Pending
- 2022-03-16 WO PCT/US2022/020479 patent/WO2022197756A1/en not_active Ceased
- 2022-03-16 JP JP2023557352A patent/JP2024510503A/ja active Pending
- 2022-03-16 US US18/550,571 patent/US20240382482A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024510503A5 (enExample) | ||
| JP2024516073A5 (enExample) | ||
| JP2022548696A5 (enExample) | ||
| JP5387699B2 (ja) | Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤 | |
| ES2892550T3 (es) | Compuestos útiles como inmunomoduladores | |
| JP2019013227A5 (enExample) | ||
| US6538116B2 (en) | C-nitroso compounds and use thereof | |
| RU2306309C2 (ru) | Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний | |
| JP2024510502A5 (enExample) | ||
| JP5330324B2 (ja) | Ｆｐアゴニストとして有用な、芳香族のあるｃ１６〜ｃ２０が置換されたテトラヒドロプロスタグランジン類 | |
| JP2024510504A5 (enExample) | ||
| JP2024512497A5 (enExample) | ||
| AU2004249639B2 (en) | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | |
| JP2020528937A5 (enExample) | ||
| JP5265518B2 (ja) | アルテミシニン誘導体の二量体、この調製およびこの治療上の使用 | |
| JP2012530703A5 (enExample) | ||
| KR20040026678A (ko) | 택솔 인핸서 화합물 | |
| JP2023506410A5 (enExample) | ||
| JP2023515888A5 (enExample) | ||
| JP2017507208A (ja) | 開環メタセシス重合のための触媒及び方法 | |
| EP1095043A1 (en) | Trioxane derivatives | |
| BR112017005713B1 (pt) | Composto de fórmula (i) e composição farmacêutica | |
| CN107141410A (zh) | 聚合物缀合的MetAP2抑制剂及其应用的治疗方法 | |
| TWI711627B (zh) | 製備環縮肽之方法 | |
| CA2587671A1 (en) | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha |